JP2024517678A - ソルチリン活性の修飾物質 - Google Patents

ソルチリン活性の修飾物質 Download PDF

Info

Publication number
JP2024517678A
JP2024517678A JP2023565327A JP2023565327A JP2024517678A JP 2024517678 A JP2024517678 A JP 2024517678A JP 2023565327 A JP2023565327 A JP 2023565327A JP 2023565327 A JP2023565327 A JP 2023565327A JP 2024517678 A JP2024517678 A JP 2024517678A
Authority
JP
Japan
Prior art keywords
acid
halo
alkyl
propanamido
acetamido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517678A5 (https=
JPWO2022223805A5 (https=
Inventor
ブライアン リトル，ポウル
ハビエル カセス－トーマス，マヌエル
フールサング キョルビー，マス
ニュケーア，アナス
Original Assignee
インスセンセ アーペーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスセンセ アーペーエス filed Critical インスセンセ アーペーエス
Publication of JP2024517678A publication Critical patent/JP2024517678A/ja
Publication of JP2024517678A5 publication Critical patent/JP2024517678A5/ja
Publication of JPWO2022223805A5 publication Critical patent/JPWO2022223805A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Sawing (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Secondary Cells (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2023565327A 2021-04-23 2022-04-22 ソルチリン活性の修飾物質 Pending JP2024517678A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21170274.1 2021-04-23
EP21170274.1A EP4079748A1 (en) 2021-04-23 2021-04-23 Modulators of sortilin activity
PCT/EP2022/060742 WO2022223805A1 (en) 2021-04-23 2022-04-22 Modulators of sortilin activity

Publications (3)

Publication Number Publication Date
JP2024517678A true JP2024517678A (ja) 2024-04-23
JP2024517678A5 JP2024517678A5 (https=) 2025-04-21
JPWO2022223805A5 JPWO2022223805A5 (https=) 2025-04-21

Family

ID=75674611

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565327A Pending JP2024517678A (ja) 2021-04-23 2022-04-22 ソルチリン活性の修飾物質

Country Status (8)

Country Link
US (1) US20240217922A1 (https=)
EP (2) EP4079748A1 (https=)
JP (1) JP2024517678A (https=)
KR (1) KR20240000510A (https=)
CN (1) CN117677627A (https=)
AU (1) AU2022260554A1 (https=)
CA (1) CA3215848A1 (https=)
WO (1) WO2022223805A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4471047A1 (en) * 2023-05-31 2024-12-04 Insusense ApS Modulators of sortilin activity
EP4361165A1 (en) * 2022-10-24 2024-05-01 Insusense ApS Modulators of sortilin activity
CN116143648A (zh) * 2022-12-05 2023-05-23 河北远大九孚生物科技有限公司 一种n-乙酰-l-苯丙氨酸的合成方法
EP4428124A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Modulators of sortilin activity
EP4428121A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Modulators of sortilin activity
EP4719366A1 (en) 2023-05-26 2026-04-08 Bertram Wiedenmann Sortilin inhibitors for treatment of patients with functional neuroendocrine tumors
TW202600557A (zh) * 2024-02-20 2026-01-01 日商大塚製藥股份有限公司 作為sort1抑制劑之哌啶-及嗎啉-羧酸鹽化合物

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63183551A (ja) * 1986-10-31 1988-07-28 ファイザー・インコーポレーテッド ノルスタチンおよびノルシクロスタチンポリペプチド
JPH02204475A (ja) * 1988-12-14 1990-08-14 Hoechst Ag 酵素‐阻害アミノ酸誘導体およびその製法
JPH05345754A (ja) * 1992-06-15 1993-12-27 Suntory Ltd ジペプチド誘導体およびそれを有効成分とする骨疾患の予防または治療剤
JP2000501938A (ja) * 1995-12-13 2000-02-22 デグッサ アクチエンゲゼルシャフト 相応するラセミ体のＤ，Ｌ―α―アミノカルボン酸から光学活性Ｌ―α―アミノカルボン酸を取得する方法
WO2004037159A2 (en) * 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
WO2006050861A2 (en) * 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
JP2009503027A (ja) * 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病ｉｉの治療のための置換エタン−１，２−ジアミン
WO2012004554A1 (en) * 2010-07-06 2012-01-12 St George's Hospital Medical School Aldehyde compounds as inhibitors of dust mite group 1 peptidase allergen and their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3309157T (pt) 2009-05-13 2019-12-02 Gilead Pharmasset Llc Compostos antivirais
CN104955456B (zh) * 2013-01-28 2018-07-03 H.隆德贝克有限公司 作为分拣蛋白抑制剂的n-取代的-5-取代的邻氨甲酰苯甲酸
WO2015131100A1 (en) 2014-02-28 2015-09-03 The Scripps Research Institute Ligand-controlled c(sp3)-h arylation and olefination in synthesis of unnatural chiral alpha amino acids
US20160331746A1 (en) 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63183551A (ja) * 1986-10-31 1988-07-28 ファイザー・インコーポレーテッド ノルスタチンおよびノルシクロスタチンポリペプチド
JPH02204475A (ja) * 1988-12-14 1990-08-14 Hoechst Ag 酵素‐阻害アミノ酸誘導体およびその製法
JPH05345754A (ja) * 1992-06-15 1993-12-27 Suntory Ltd ジペプチド誘導体およびそれを有効成分とする骨疾患の予防または治療剤
JP2000501938A (ja) * 1995-12-13 2000-02-22 デグッサ アクチエンゲゼルシャフト 相応するラセミ体のＤ，Ｌ―α―アミノカルボン酸から光学活性Ｌ―α―アミノカルボン酸を取得する方法
WO2004037159A2 (en) * 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
WO2006050861A2 (en) * 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
JP2009503027A (ja) * 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病ｉｉの治療のための置換エタン−１，２−ジアミン
WO2012004554A1 (en) * 2010-07-06 2012-01-12 St George's Hospital Medical School Aldehyde compounds as inhibitors of dust mite group 1 peptidase allergen and their use

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS ON STN, AN 1928:22055, DN 22:22055, FERMENTFORSCHUNG, 1928, 9, 430-8, JPN6026004885, ISSN: 0005793409 *
DATABASE CAPLUS ON STN, AN 1929:25099, DN 23:25099, FERMENTFORSCHUNG, 1929, 10, 365-95, JPN6026004884, ISSN: 0005793408 *
DATABASE CAPLUS ON STN, AN 1929:27095, DN 23:27095, FERMENTFORSCHUNG, 1929, 10, 464-73, JPN6026004883, ISSN: 0005793407 *
DATABASE CAPLUS ON STN, AN 1930:14771, DN 24:14771, FERMENTFORSCHUNG, 1930, 11, 183-223, JPN6026004882, ISSN: 0005793406 *
DATABASE CAPLUS ON STN, AN 1930:14910, DN 24:14910, FERMENTFORSCHUNG, 1930, 11, 251-66, JPN6026004881, ISSN: 0005793405 *
DATABASE CAPLUS ON STN, AN 1933:2403, DN 27:2403, FERMENTFORSCHUNG, 1932, 13, 443-50, JPN6026004879, ISSN: 0005793403 *
DATABASE CAPLUS ON STN, AN 1933:684, DN 27:684, FERMENTFORSCHUNG, 1932, 13, 330-62, JPN6026004880, ISSN: 0005793404 *
DATABASE CAPLUS ON STN, AN 1978:33773, DN 88:33773, PROCEEDINGS OF THE HUNGARIAN ANNUAL MEETING FOR, JPN6026004878, ISSN: 0005793402 *
DATABASE REGISTRY ON STN, RN 1940181-83-8, 2016, JPN6026004896, ISSN: 0005793417 *
DATABASE REGISTRY ON STN, RN 1940994-16-0, 2016, JPN6026004895, ISSN: 0005793416 *
DATABASE REGISTRY ON STN, RN 2030882-40-5, 2016, JPN6026004894, ISSN: 0005793415 *
DATABASE REGISTRY ON STN, RN 2032057-45-5, 2016, JPN6026004893, ISSN: 0005793414 *
DATABASE REGISTRY ON STN, RN 2032696-48-1, 2016, JPN6026004891, ISSN: 0005793413 *
DATABASE REGISTRY ON STN, RN 2034726-96-8, 2016, JPN6026004897, ISSN: 0005793418 *
DATABASE REGISTRY ON STN, RN 2037181-89-6, 2016, JPN6026004889, ISSN: 0005793412 *
DATABASE REGISTRY ON STN, RN 2038174-17-1, 2016, JPN6026004888, ISSN: 0005793411 *
DATABASE REGISTRY ON STN, RN 2039341-52-9, 2016, JPN6026004886, ISSN: 0005793410 *
HETEROCYCLES, vol. 33, no. 2, JPN6026004876, 1992, pages 657 - 671, ISSN: 0005793400 *
J MED CHEM, vol. 43, JPN6026004875, 2000, pages 664 - 674, ISSN: 0005793399 *
J MED CHEM, vol. 60, JPN6026004872, 2017, pages 6721 - 6732, ISSN: 0005793397 *
JOURNAL OF CHROMATOGRAPHY A, vol. 1428, JPN6026004874, 2016, pages 176 - 184, ISSN: 0005793398 *
JOURNAL OF ORGANIC CHEMISTRY, vol. 18, JPN6026004877, 1953, pages 127 - 132, ISSN: 0005793401 *

Also Published As

Publication number Publication date
US20240217922A1 (en) 2024-07-04
AU2022260554A1 (en) 2023-11-02
EP4079748A1 (en) 2022-10-26
EP4326742A1 (en) 2024-02-28
AU2022260554A9 (en) 2023-11-16
CN117677627A (zh) 2024-03-08
WO2022223805A1 (en) 2022-10-27
CA3215848A1 (en) 2022-10-27
KR20240000510A (ko) 2024-01-02

Similar Documents

Publication Publication Date Title
JP2024517678A (ja) ソルチリン活性の修飾物質
US20240294569A1 (en) Modulators of sortilin activity
EP3983384B1 (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
JP7187575B2 (ja) Ｒｈｏキナーゼ阻害剤としてのベンゾピラゾール系化合物
KR20190005838A (ko) 이중 lsd1/hdac 억제제로서 사이클로프로필-아마이드 화합물
KR20200142022A (ko) 6-아미노이소퀴놀린의 일가-(산) 염 및 이의 용도
JP7030776B2 (ja) アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用
KR20240115978A (ko) Lpa 수용체 길항제 및 이의 용도
JP2024537619A (ja) 中枢神経系の疾患の処置における使用のためのソルチリンモジュレーターとしての２－アミノ－５，５－ジメチルヘキサン酸誘導体
JP2025508927A (ja) ソルチリン依存性疾患を治療するためのアミノ酸ベースのカルバメート及び／又は尿素
EP4281460A1 (en) Pyridine derivatives as modulators of sortilin activity
CA2804001C (en) Methods for treating post traumatic stress disorder
EP4428121A1 (en) Modulators of sortilin activity
WO2024184468A1 (en) Modulators of sortilin activity
JP2026067760A (ja) Ｃ３ａ受容体拮抗化合物及びその利用
JP2010180177A (ja) 環状アミノピラゾールアミド誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210